Similar NF-κB Gene Signatures in TNF-α Treated Human Endothelial Cells and Breast Tumor Biopsies

Background Endothelial dysfunction has been implicated in the pathogenesis of diverse pathologies ranging from vascular and immune diseases to cancer. TNF-α is one of the mediators of endothelial dysfunction through the activation of transcription factors, including NF-κB. While HUVEC (macrovascular cells) have been largely used in the past, here, we documented an NF-κB gene signature in TNFα-stimulated microvascular endothelial cells HMEC often used in tumor angiogenesis studies. Methodology/Principal Findings We measured mRNA expression of 55 NF-κB related genes using quantitative RT-PCR in HUVEC and HMEC. Our study identified twenty genes markedly up-regulated in response to TNFα, including adhesion molecules, cytokines, chemokines, and apoptosis regulators, some of them being identified as TNF-α-inducible genes for the first time in endothelial cells (two apoptosis regulators, TNFAIP3 and TNFRSF10B/Trail R2 (DR5), the chemokines GM-CSF/CSF2 and MCF/CSF1, and CD40 and TNF-α itself, as well as NF-κB components (RELB, NFKB1or 50/p105 and NFKB2 or p52/p100). For eight genes, the fold induction was much higher in HMEC, as compared to HUVEC. Most importantly, our study described for the first time a connection between NF-κB activation and the induction of most, if not all, of these genes in HMEC as evaluated by pharmacological inhibition and RelA expression knock-down by RNA interference. Moreover, since TNF-α is highly expressed in tumors, we further applied the NF-κB gene signature documented in TNFα-stimulated endothelial cells to human breast tumors. We found a significant positive correlation between TNF and the majority (85 %) of the identified endothelial TNF-induced genes in a well-defined series of 96 (48 ERα positive and 48 ERα negative) breast tumors. Conclusion/Significance Taken together these data suggest the potential use of this NF-κB gene signature in analyzing the role of TNF-α in the endothelial dysfunction, as well as in breast tumors independently of the presence of ERα.

[1]  Michael Karin,et al.  NF-kappaB in cancer: from innocent bystander to major culprit. , 2002, Nature reviews. Cancer.

[2]  T. Shono,et al.  Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis , 1997, Molecular and cellular biology.

[3]  G. Courtois,et al.  Inhibition of IκB Kinase Subunit 2 in Cutaneous T-Cell Lymphoma Down-Regulates Nuclear Factor-κB Constitutive Activation, Induces Cell Death, and Potentiates the Apoptotic Response to Antineoplastic Chemotherapeutic Agents , 2008, Clinical Cancer Research.

[4]  Michael Karin,et al.  NF-κB in cancer: from innocent bystander to major culprit , 2002, Nature Reviews Cancer.

[5]  Yang Gao,et al.  Genomic-scale analysis of gene expression profiles in TNF-α treated human umbilical vein endothelial cells , 2002, Inflammation Research.

[6]  K. Tracey,et al.  Tumor necrosis factor, other cytokines and disease. , 1993, Annual review of cell biology.

[7]  S. Lenhoff,et al.  Cytokine regulation of GM-CSF and G-CSF secretion by human umbilical cord vein endothelial cells (HUVEC). , 1996, Cytokine.

[8]  I. Bièche,et al.  Quantification of estrogen receptor α and β expression in sporadic breast cancer , 2001, Oncogene.

[9]  Sankar Ghosh,et al.  Signaling to NF-kappaB. , 2004, Genes & development.

[10]  C. Ferran,et al.  Overexpression of A1, an NF-κB–Inducible Anti-Apoptotic Bcl Gene, Inhibits Endothelial Cell Activation , 1999 .

[11]  W. Funkhouser,et al.  Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. , 2000, Oncogene.

[12]  E. Bröcker,et al.  Multiple signaling pathways regulate NF-kappaB-dependent transcription of the monocyte chemoattractant protein-1 gene in primary endothelial cells. , 2001, Blood.

[13]  Michael Karin,et al.  NF-κB at the crossroads of life and death , 2002, Nature Immunology.

[14]  D. Green,et al.  The Lymphotoxin-β Receptor Induces Different Patterns of Gene Expression via Two NF-κB Pathways , 2002 .

[15]  D. Stern.  ERBB3/HER3 and ERBB2/HER2 Duet in Mammary Development and Breast Cancer , 2008, Journal of Mammary Gland Biology and Neoplasia.

[16]  A. E. Rogers,et al.  Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. , 1997, The Journal of clinical investigation.

[17]  W. Funkhouser,et al.  Selective activation of NF-κB subunits in human breast cancer: potential roles for NF-κB2/p52 and for Bcl-3 , 2000, Oncogene.

[18]  M. Gerritsen,et al.  Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. , 1997, The Journal of biological chemistry.

[19]  D. Chi,et al.  Multifunctional cytokine expression by human coronary endothelium and regulation by monokines and glucocorticoids. , 1998, Microvascular research.

[20]  T. Giordano,et al.  NF-κB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF , 2007, Nature Medicine.

[21]  M. Gerritsen,et al.  Novel Inhibitors of Cytokine-induced IκBα Phosphorylation and Endothelial Cell Adhesion Molecule Expression Show Anti-inflammatory Effects in Vivo* , 1997, The Journal of Biological Chemistry.

[22]  S. Vacher,et al.  CXC chemokines located in the 4q21 region are up-regulated in breast cancer. , 2007, Endocrine-related cancer.

[23]  R. Serra,et al.  TGF-β in Mammary Gland Development and Breast Cancer , 2003 .

[24]  Johannes Roth,et al.  TNF induces distinct gene expression programs in microvascular and macrovascular human endothelial cells , 2006, Journal of leukocyte biology.

[25]  A. Eggermont,et al.  Tumor necrosis factor‐mediated interactions between inflammatory response and tumor vascular bed , 2008, Immunological reviews.

[26]  D. Green,et al.  RelB/p50 dimers are differentially regulated by tumor necrosis factor-alpha and lymphotoxin-beta receptor activation: critical roles for p100. , 2003, The Journal of biological chemistry.

[27]  A. Baldwin.  Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. , 2001, The Journal of clinical investigation.

[28]  M. Karin,et al.  NF-κB in Mammary Gland Development and Breast Cancer , 2003, Journal of Mammary Gland Biology and Neoplasia.

[29]  J. Hamilton,et al.  GM-CSF in inflammation and autoimmunity. , 2002, Trends in immunology.

[30]  A. Karsan,et al.  Cloning of human Bcl-2 homologue: inflammatory cytokines induce human A1 in cultured endothelial cells. , 1996, Blood.

[31]  D. Ribatti,et al.  Analysis of the role of chemokines in angiogenesis. , 2003, Journal of immunological methods.

[32]  A. Prat,et al.  Death receptor expression and function at the human blood brain barrier , 2007, Journal of the Neurological Sciences.

[33]  R. Locksley,et al.  The TNF and TNF Receptor Superfamilies Integrating Mammalian Biology , 2001, Cell.

[34]  H. Pahl,et al.  Activators and target genes of Rel/NF-kappaB transcription factors. , 1999, Oncogene.

[35]  V. Baichwal,et al.  Regulatory elements and transcription factors controlling basal and cytokine-induced expression of the gene encoding intercellular adhesion molecule 1. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[36]  H. Saji,et al.  Significant correlation of monocyte chemoattractant protein‐1 expression with neovascularization and progression of breast carcinoma , 2001, Cancer.

[37]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[38]  M. Rots,et al.  Differential effects of NF-{kappa}B and p38 MAPK inhibitors and combinations thereof on TNF-{alpha}- and IL-1{beta}-induced proinflammatory status of endothelial cells in vitro. , 2005, American journal of physiology. Cell physiology.

[39]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.

[40]  Hong-shan Wang,et al.  BAFF-induced NEMO-independent processing of NF-κB2 in maturing B cells , 2002, Nature Immunology.

[41]  Hong-shan Wang,et al.  BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. , 2002, Nature immunology.

[42]  M. Karin,et al.  Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. , 2009 .

[43]  R. Medford,et al.  Activation of RelA homodimers by tumour necrosis factor alpha: a possible transcriptional activator in human vascular endothelial cells. , 2005, The Biochemical journal.

[44]  P. Quesenberry,et al.  Vascular endothelium as a regulator of granulopoiesis: production of colony-stimulating activity by cultured human endothelial cells. , 1980, Blood.

[45]  M. Feldmann,et al.  RelB/p50 regulates CCL19 production, but fails to promote human DC maturation , 2009, European journal of immunology.

[46]  H. Pahl.  Activators and target genes of Rel/NF-κB transcription factors , 1999, Oncogene.

[47]  W. V. Berghe,et al.  Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6. , 2000, Biochemical pharmacology.

[48]  M. Karin,et al.  Signal transduction by tumor necrosis factor and its relatives. , 2001, Trends in cell biology.

[49]  E. Jaffe,et al.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. , 1973, The Journal of clinical investigation.

[50]  P. Romeo,et al.  RelA repression of RelB activity induces selective gene activation downstream of TNF receptors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[51]  D. Green,et al.  RelB/p50 dimers are differentially regulated by TNF-α and lymphotoxin-β receptor activation: critical roles for p100 , 2003 .

[52]  M. Rossol,et al.  Interaction between Transmembrane TNF and TNFR1/2 Mediates the Activation of Monocytes by Contact with T Cells1 , 2007, The Journal of Immunology.

[53]  H. Ledebur,et al.  Transcriptional Regulation of the Intercellular Adhesion Molecule-1 Gene by Inflammatory Cytokines in Human Endothelial Cells , 1995, The Journal of Biological Chemistry.

[54]  B. Aggarwal,et al.  Nuclear factor-kappaB activation mediates cellular transformation, proliferation, invasion angiogenesis and metastasis of cancer. , 2004, Cancer treatment and research.

[55]  D. Green,et al.  The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. , 2002, Immunity.

[56]  Q. Yao,et al.  TNF-alpha induces interleukin-8 and endothelin-1 expression in human endothelial cells with different redox pathways. , 2005, Biochemical and biophysical research communications.

[57]  R. Ross,et al.  Apoptosis overrides survival signals through a caspase-mediated dominant-negative NF-kappa B loop. , 1999, Nature cell biology.

[58]  Michael Karin,et al.  Is NF-κB a good target for cancer therapy? Hopes and pitfalls , 2009, Nature Reviews Drug Discovery.

[59]  Shaomeng Wang,et al.  Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-kappaB and CXC chemokines. , 2005, Cancer research.

[60]  A. Karsan,et al.  Endothelial Cell Death Induced by Tumor Necrosis Factor-α Is Inhibited by the Bcl-2 Family Member, A1* , 1996, The Journal of Biological Chemistry.

[61]  C. Ferran,et al.  Overexpression of A1, an NF-kappaB-inducible anti-apoptotic bcl gene, inhibits endothelial cell activation. , 1999, Blood.

[62]  H. Bloom,et al.  Histological Grading and Prognosis in Breast Cancer , 1957, British Journal of Cancer.

[63]  I. Bièche,et al.  Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer. , 2001, Oncogene.

[64]  J. Russo,et al.  Activation of NF-kappaB/Rel occurs early during neoplastic transformation of mammary cells. , 2000, Carcinogenesis.

[65]  R. Ross,et al.  Apoptosis overrides survival signals through a caspase-mediated dominant-negative NF-κB loop , 1999, Nature Cell Biology.

[66]  Rosette Lidereau,et al.  Molecular Profiling of Inflammatory Breast Cancer , 2004, Clinical Cancer Research.

[67]  N. Perkins,et al.  Regulation of p53 tumour suppressor target gene expression by the p52 NF‐κB subunit , 2006, The EMBO journal.

[68]  B. Aggarwal,et al.  Nuclear factor-kappaB: the enemy within. , 2004, Cancer cell.

[69]  P. Mangeot,et al.  Expression of Pitx2 in stromal cells is required for normal hematopoiesis. , 2006, Blood.

[70]  Carlo Riccardo Rossi,et al.  Tumor necrosis factor, cancer and anticancer therapy. , 2005, Cytokine & growth factor reviews.